Journal of proteome research letters

Peripheral Neuropathy and Light—Preliminary Report Indicating Prevalence of Nanobacteria in HIV

Andrei P. Sommer*

Central Institute of Biomedical Engineering, University of Ulm, 89081 Ulm, Germany

Received August 6, 2003

Peripheral neuropathy is a common condition in HIV-positive patients and is often experienced in diabetes mellitus. The primary mechanism of the disease, which can considerably aggravate the patient's state, is unknown. The perineurium of patients with peripheral neuropathy is frequently enveloped by apatite. Nanobacteria (NB) are protectd by a mineral shell consisting of apatite. Light has been shown to elevate the vitality level of cells, and was predicted to inhibit deposition of stressed NB in the cardiovascular system. Results indicate that light can durably restore the condition of patients with severe peripheral neuropathy.

Keywords: peripheral neuropathy • nanobacteria • diabetes mellitus • HIV • AIDS

[illegible]

* To [illegible] E-[illegible]

10.1021/pr0340633 CCC: $25.00 © 2003 American Chemical Society **Journal of Proteome Research** *2003, 2, 665−666* **665**
Published on Web 10/14/2003

[illegible]

A 38% [illegible] [14] [illegible] [1] [illegible] [8,9] [illegible] [12] [illegible] [13] [illegible]

[illegible]

References

(1) [illegible] B. S. *Circulation* **2003**, *107*, [illegible]74.
(2) [illegible] A.; [illegible] M. *Acta Neuropathol. (Berl).* 1**976**, *36*, 185.
(3) [illegible] H.; [illegible] J.; [illegible] A.; [illegible] M. *Muscle Nerve* **1981**, *4*, 228.
(4) [illegible] A. P.; [illegible] E. O.; [illegible] A. R. *J. Proteome Res.* **2002**, *1*, 475.
(5) [illegible] A. P.; [illegible] H. I.; [illegible] E. O. *J. Clin. Laser Med. Surg.* **2002**, *20*, 241.
(6) [illegible] A. P.; [illegible] A. M.; [illegible] D. S.; [illegible] N.; [illegible] A. R.; [illegible] E. O.; [illegible] H. T. J [illegible]. *Clin. Laser Med. Surg.* **2003**, *21*, 229.
(7) [illegible] A. P.; [illegible] A. M.; [illegible] E. O.; [illegible] *Cryst. Growth Des.*, [illegible]
(8) [illegible] *AIDS* **2003**, *Suppl. 1*, S65.
(9) [illegible] D.; [illegible] L.; [illegible] G.; [illegible] E.; [illegible] J. J.; [illegible] M.; [illegible] A. *AIDS* **2003**, *Suppl. 1*, S70.
(10) [illegible] A. P.; [illegible] A. L. B.; [illegible] A. R.; [illegible] R. P. [illegible] H. T. *J. Clin. Laser Med. Surg.* **2001**, *19*, 29.
(11) [illegible] F. A. H. [illegible] 2001, [illegible] *NASA Conference Publication*, 2002, CP-2002-210786, 70.
(12) [illegible] A. P.; [illegible] D. S.; [illegible] N.; [illegible] A. R.; [illegible] E. O. *J. Proteome Res.* **2003**, *2*, 441.
(13) [illegible] A. P.; [illegible] A. E. *J. Proteome Res.* **2003**, *2*, 558.
(14) [illegible] H. C.; [illegible] A. M.; [illegible] J. A.; [illegible] D. [illegible] J. G. *Radiology* **2002**, *224*, 236.

PR0340633